4.7 Article

Smoking as a major risk factor for cervical cancer and pre-cancer: Results from the EPIC cohort

Journal

INTERNATIONAL JOURNAL OF CANCER
Volume 135, Issue 2, Pages 453-466

Publisher

WILEY
DOI: 10.1002/ijc.28666

Keywords

cohort study; cervical cancer; smoking; Human Papillomavirus serology; EPIC

Categories

Funding

  1. Merck/SPMSD
  2. MSD/Merck
  3. Merck Co., Inc
  4. SPMSD
  5. Instituto de Salud Carlos III (Spanish Government) [FIS PI08/1308, RCESP C03/09, RTICESP C03/10, RTIC RD06/0020/0095, RD12/0036/0056, RD12/0036/0018, CIBERESP]
  6. Agencia de Gestio d'Ajuts Universitaris i de Recerca-Generalitat de Catalunya (Catalonian Government) [AGAUR 2005SGR00695, 2009SGR939, 2009SGR126]
  7. European Commission (DG-SANCO)
  8. International Agency for Research on Cancer
  9. Health Research Fund (FIS) of the Spanish Ministry of Health [Exp P10710130]
  10. Regional Government of Andalucia
  11. Regional Government of Asturias
  12. Regional Government of Basque Country
  13. Regional Government of Murcia
  14. Regional Governments of Navarra
  15. Catalan Institute of Oncology [6236]
  16. La Caixa (Spain) [BM 06-130, RTICC-RD06/10091]
  17. Danish Cancer Society (Denmark)
  18. Ligue contre le Cancer
  19. Mutuelle Generale de l'Education Nationale
  20. Institut National de la Sante et de la Recherche Medicale (INSERM) (France)
  21. Deutsche Krebshilfe
  22. Deutsches Krebsforschungszentrum
  23. Hellenic Health Foundation (Greece)
  24. Italian Association for Research on Cancer (AIRC)
  25. National Research Council (Italy)
  26. Dutch Ministry of Public Health
  27. Welfare and Sports
  28. Netherlands Cancer Registry (NKR)
  29. LK Research Funds
  30. Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland)
  31. World Cancer Research Fund (WCRF)
  32. Regional Government of Skane and Vasterbotten (Sweden)
  33. Cancer Research UK, Medical Research Council (United Kingdom)
  34. Norwegian Research Council, Norwegian Cancer Society, University of Tromso (Norway)
  35. Institut Gustave Roussy
  36. Federal Ministry of Education and Research (Germany)
  37. Statistics Netherlands (The Netherlands)
  38. Swedish Cancer Society
  39. Swedish Scientific Council
  40. Cancer Research UK [16491, 14136] Funding Source: researchfish
  41. Medical Research Council [G1000143, G0401527] Funding Source: researchfish
  42. National Institute for Health Research [NF-SI-0512-10114] Funding Source: researchfish

Ask authors/readers for more resources

A total of 308,036 women were selected from the European Prospective Investigation into Cancer and Nutrition (EPIC) study to evaluate the association between tobacco smoking and the risk of cervical intraepithelial neoplasia of grade 3 (CIN3)/carcinoma in situ (CIS) and invasive cervical cancer (ICC). At baseline, participants completed a questionnaire and provided blood samples. During a mean follow-up time of 9 years, 261 ICC cases and 804 CIN3/CIS cases were reported. In a nested case-control study, the baseline sera from 609 cases and 1,218 matched controls were tested for L1 antibodies against HPV types 11, 16, 18, 31, 33, 35, 45, 52, 58, and antibodies against Chlamydia trachomatis (CT), and Human Herpes Virus 2 (HHV-2). Cervical samples were not available for HPV-DNA analysis in this study. Multivariate analyses were used to estimate associations between smoking and risk of CIN3/CIS and ICC in the cohort and the case-control studies. In the cohort analyses smoking status, duration and intensity showed a two-fold increased risk of CIN3/CIS and ICC, while time since quitting was associated with a two-fold reduced risk. In the nested case-control study, consistent associations were observed after adjustment for HPV, CT and HHV-2 serostatus, in both HPV seronegative and seropositive women. Results from this large prospective study confirm the role of tobacco smoking as an important risk factor for both CIN3/CIS and ICC, even after taking into account HPV exposure as determined by HPV serology. The strong beneficial effect of quitting smoking is an important finding that will further support public health policies for smoking cessation. What's new? Tobacco smoking is a cited cause of cervical cancer, but whether it causes cervical malignancy independent of human papillomavirus (HPV) infection is unclear. Here, strong associations were found between most measures of tobacco smoking and the risk of cervical intraepithelial neoplasia of grade 3/carcinoma in situ and invasive cervical cancer, after taking into account past exposure to HPV infection. Quitting smoking was associated with a 2-fold risk reduction. The findings confirm the role of tobacco smoking in cervical carcinogenesis and show that quitting the habit has important benefits for cancer protection.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available